Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
Phase III, comparative, multicenter, randomized, controlled, double-blind and superiority
research, comparing rituximab-based regimen with conventional therapeutic strategy for the
induction of remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Patients with newly diagnosed or relapsing EGPA will be randomized in a 1:1 ratio to receive:
- Experimental therapeutic strategy based on the use of rituximab (experimental group)
- Conventional therapeutic strategy based on Five-Factor Score (FFS)-assessed disease
severity (comparative group)
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
French Vasculitis Study Group French Vasculitis Study Group (FVSG)